Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 20, Issue 3, Pages 381-394Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/13543784.2011.541154
Keywords
dual-kinase PI3K-mTOR inhibitors; mammalian target of rapamycin; mTORC1/mTORC2 inhibitors; rapalogs; renal cell carcinoma
Categories
Ask authors/readers for more resources
Areas covered: This paper provides a review of the published literature on the mTOR pathway and related pathway signaling, analogs and novel mTOR inhibitors. The most recent and important data on the mTOR pathway, the role of mTOR inhibitors in cancer treatment and the current status of development of second-generation highly potent and selective mTOR inhibitors are overviewed. Expert opinion: The published data on new mTOR inhibitors are still limited, but the available preclinical results indicate that they have a potent antiproliferative activity against a broad panel of tumor cell lines, have a favorable safety profile, can obtain disease stabilization or even tumor regression and, in some cases, enhance the efficacy of other targeted or standard-of-care anticancer drugs when used in vivo in preclinical studies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available